Renishaw Diagnostics to present at PittCon 2011,
the world's largest annual conference and
exposition for laboratory science
Glasgow, Scotland, 7 March 2011: Renishaw Diagnostics Ltd (formerly D3 Technologies), a world
leading provider of trace level detection technologies based on the exploitation of surface enhanced
Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS), for research
and molecular diagnostics applications, today announced details of a talk to be presented at PittCon
2011 in Atlanta, Georgia later this month.
Dr David Eustace, the company’s Project Leader for Development, will present on the development of
multiple-target antibody-based diagnostic assays, which utilise SERS as the detection mechanism. He
will also discuss the application of SERRS in a multiplex assay system for detection and diagnosis of
infectious diseases.
He said “We are very pleased to be selected to present at PittCon to showcase some of the scientific
developments taking place at Renishaw Diagnostics. Only last month we announced the launch of our
RenDx™ multiplex analysis system for research use only that offers scientists a very sensitve, specific
and flexible tool to screen for numerous targets in a single assay. It is a truly transformative technology
introduction, in advance of our fully regulated RenDx system for human diagnostics that is in advanced
stages of development.
“In the antibody-based assays, sensitivity to below pg/ml levels has been demonstrated and this allows
multiple antigen targets to be identified. The system is based on a modified sandwich ELISA platform
and has been developed as a transferable technology, applicable in several diagnostics sectors.
Results of testing for matrix metalloproteinases (MMPs), and additional targets in spiked and clinical
samples, have demonstrated the robustness and versatility of the technology.”
Renishaw Diagnostics, who will share exhibition space with the US subsidiary of parent company
Renishaw plc on booth number 1253, will also be promoting their patented SERS substrate, Klarite®,
which provides a very sensitive and reproducible platform for analysing and identifying chemical
compounds. Klarite SERS substrates are widely used for academic and industrial trace element
applications and the company has an active partnership program to further exploit the benefits of this
technology for applications in biopharmaceutical manufacturing clean up, environmental, forensics and
security.
About PittCon
Pittcon is the world's largest annual conference and exposition for laboratory science. Pittcon 2011 will
offer the latest technology and instrumentation from more than 950 exhibitors, a diverse Technical
Program of over 2,200 abstracts to technical presentations, over 100 Short Courses to enhance your
educational experience, and networking sessions that provide the chance to exchange innovative ideas
with scientists from around the world. Further information is available at http://www.pittcon.org/
About Renishaw Diagnostics Ltd
Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a Strathclyde University spin-out before
being acquired by the Renishaw Group, which is a leading global supplier of engineering technologies,
medical devices and Raman spectroscopy systems. It is focused on developing and commercialising its
first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw
Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics
products for the detection of human infectious diseases. The company is based in Glasgow, Scotland,
and further information is available at www.renishawdiagnostics.com.
For further information, contact:
Jim Greaves, Head of Marketing
jim.greaves@renishawdiagnostics.com